Journal article

Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine

Carolien E van de Sandt, Joost HCM Kreijtz, Martina M Geelhoed-Mieras, Stella E Vogelzang-van Trierum, Nella J Nieuwkoop, David AMC van de Vijver, Ron AM Fouchier, Albert DME Osterhaus, Bror Morein, Guus F Rimmelzwaan

Vaccine | ELSEVIER SCI LTD | Published : 2014

Abstract

Vaccines used against seasonal influenza are poorly effective against influenza A viruses of novel subtypes that may have pandemic potential. Furthermore, pre(pandemic) influenza vaccines are poorly immunogenic, which can be overcome by the use of adjuvants. A limited number of adjuvants has been approved for use in humans, however there is a need for alternative safe and effective adjuvants that can enhance the immunogenicity of influenza vaccines and that promote the induction of broad-protective T cell responses. Here we evaluated a novel nanoparticle, G3, as an adjuvant for a seasonal trivalent inactivated influenza vaccine in a mouse model. The G3 adjuvant was formulated with or without..

View full abstract